Tvaster Genkalp Secures $1.25 Mn to Expand Liquid Biopsy Cancer Diagnostics

The investment aims to accelerate the expansion and commercialization of Episcreen Liver, a methylation-based liquid biopsy test designed for early detection of hepatocellular carcinoma (HCC), the most common form of liver cancer.

Tvaster Genkalp, a Chennai-based molecular diagnostics startup, has raised $1.25 million in a Pre-Series A funding round led by Ideaspring Capital.

Existing investors include Invigo Softwares and liver transplant specialist Prof. Mohamed Rela.

The investment aims to accelerate the expansion and commercialization of Episcreen Liver, a methylation-based liquid biopsy test designed for early detection of hepatocellular carcinoma (HCC), the most common form of liver cancer.

“The funding will accelerate nationwide deployment of Episcreen Liver, offering a non-invasive, highly accurate diagnostic alternative for hepatocellular carcinoma,” said Dr. Srikar Raman, Co-founder of Tvaster Genkalp.

According to Dr Raman, while the current standard screening method, Alpha-Fetoprotein (AFP), has a sensitivity of 50%, Episcreen Liver achieves 90% sensitivity, significantly improving early detection and increasing survival chances by over 70%.

New Diagnostics Pipeline for Oncology

Tvaster is also developing additional oncology diagnostic solutions. The company is advancing its pipeline with Episcreen Bile, a test for cholangiocarcinoma, an aggressive bile duct cancer with limited early detection options.

Additionally, Tvaster has introduced Episcreen HBResist, the first chemotherapy resistance test for pediatric hepatoblastoma, addressing a critical gap in childhood cancer treatment.

To expand accessibility, the company is establishing partnerships with leading diagnostic companies.